

Phenotypic Heterogeneity of *RRM2B* Mutations

Josef Finsterer¹, Sinda Zarrouk-Mahjoub²

¹Krankenanstalt Rudolfstiftung, Vienna, Austria

²University of Tunis El Manar and Genomics Platform, Pasteur Institute of Tunis, Tunisia

Keywords: Mitochondrial, mtDNA, Phenotype, Genotype, Myopathy, Muscle Biopsy, Pregnancy.

Letter to the Editor

In a recent article Kropach *et al.* reported about two brothers, carrying a novel *RRM2B* mutation, which manifested as fatal encephalomyopathy with hypotonia, lactic acidosis, and developmental delay [1]. The study raises a number of comments and concerns.

We should be informed if genetic testing was also carried out in patient-1 or other first-degree relatives. Did the mutation occur in the homozygous or heterozygous state? Did patient-2 inherit the mutation from his father, mother, or both? Which was the amount of mtDNA depleted? Which other family members were clinically affected?

MIDs are usually multisystem diseases (MIMODS) [2]. Did the authors also prospectively look for cardiac, endocrine, hematological, orthopedic, dermal, or pulmonary involvement? Patients carrying *RRM2B* mutations not only manifest with features observed in Kropach’s patients but also with other features (Table 1).

Patient-1 presented with focal seizures [1]. He received midazolam, hydantoin and phenobarbital [1]. Hydantoin and phenobarbital are potentially mitochondrion-toxic [3]. Did the phenotype deteriorate upon application of these compounds?

Seizures may be a manifestation of stroke-like episodes/ lesions (SLEs/SLLs) [4]. Did patient-1 undergo cerebral MRI at the time seizures occurred and did it show SLLs?

Patient-1 had marked hyper-CKemia but no EMG is reported [1]. Was hyper-CKemia due to epilepsy, myopathy, or due to both? Were fatigue, exercise intolerance, cramps, or myalgia observed? Was respiratory failure due to affection of respiratory muscles, brain-stem involvement, or due to infection or heart failure?

Overall, these interesting two cases would be more meaningful by providing data about prospective investigations for MIMODS, about the family history, and more extensive genetic work-up [5-15].

There are no conflicts of interest.

Both authors contributed equally.

No funding was received.

Table 1. Phenotypic manifestations of RRM2B mutations.

	Manifestation	Patient 1	Patient 2	Literature	
Central nervous system	Hypotonia	yes	yes	[1]	
	Missed milestones§	yes	nm	[1]	
	Absent social smile	yes	nm	[1,5]	
	Not recognising parents	yes	nm	[1]	
	Head lag	yes	yes	[6]	
	Recurrent vomiting	yes	yes	[7,8]	
	Seizures	yes	nm	[1]	
	Abnormal pacing reflexes	nm	yes	[1]	
	Abnormal stepping reflexes	nm	yes	[1]	
	Failure to thrive	yes	nm	[9]	
	Failure to gain weight	yes	yes	[1]	
	Nystagmus	nm	nm	[10]	
	Dystonia	nm	nm	[10]	
	Brisk tendon reflexes	nm	nm	[10]	
	Microcephaly	nm	nm	[1]	
	Eyes	Elevated CSF protein	yes	yes	[1]
Abnormal EEG		yes	no	[1,5]	
Abnormal cerebral MRI		no	no	[6]	
Cerebral hypomyelination		no	no	[11,12]	
Cerebral atrophy		no	no	[9]	
MRS lactate peak		nm	yes	[6]	
Myopia		nm	no	[5]	
Megacornea		nm	no	[9]	
Ears		Deafness	nm	yes	[1]
		Gastrointestinal	Dysmotility	nm	nm
Diarrhoea	nm		nm	[7]	
Renal	Hypocalcemia		yes	no	[1]
	Keton bodies	yes	yes	[5]	

	Microalbuminuria	no	yes	[1]
	Aminoaciduria	no	yes	[1]
	Fanconi-like tubular dysfunction	no	yes	[1]
	Nephrocalcinosis	nm	yes	[1]
	Glucosuria	no	yes	[1]
Hematological				
	Anemia	nm	nm	[13]
Myopathy				
	Reduced tendon reflexes	yes	yes*	[1]
	Limb muscle weakness	nm	nm	[1,5]
	Ophthalmoplegia	nm	nm	[11,12]
	Ptoxis	nm	nm	[11,12]
	Hyper-CKemia	yes	no	[13]
Neuropathy	no	no	[11,12,14]	
Others				
	Lactic acidosis	yes*	yes	[1]
	Elevated serum pyruvate	yes	no	[1]
	Elevated amino-acids	no	yes	[1]
	Increased urinary organic acids	yes	no	[1]
	Dysmorphism	yes	nm	[1]
	Respiratory failure	yes	yes	[1]
	MtDNA depletion (AR)	yes	yes	[1]
	MtDNA multiple deletions (AD)	nm	nm	[1]
	Dysphagia	nm	nm	[15]

AD: autosomal dominant transmission, AR: autosomal recessive transmission, *: not initially, §: developmental delay, nm: not mentioned

Author contribution: JF: design, literature search, discussion, first draft, SZ-M: literature search, discussion, critical comments

References

1. Kropach N, Shkalim-Zemer V, Orenstein N, et al. Novel RRM2B Mutation and Severe Mitochondrial DNA Depletion: Report of 2 Cases and Review of the Literature. *Neuropediatrics*. 2017
2. Finsterer J, Zarrouk-Mahjoub S. Mitochondrial Disorders May Mimic Amyotrophic Lateral Sclerosis at Onset. *Sultan Qaboos Univ Med J*. 2016; 16: e92-5.
3. Finsterer J. Toxicity of Antiepileptic Drugs to Mitochondria. *Handb Exp Pharmacol* 2016, (in press).
4. Finsterer J, Wakil SM. Stroke-like episodes, peri-episodic seizures, and MELAS mutations. *Eur J Paediatr Neurol*. 2016; 20: 824-829.
5. Kollberg G, Darin N, Benan K, et al. A novel homozygous RRM2B missense mutation in association with severe mtDNA depletion. *Neuromuscul Disord*. 2009; 19: 147-150.
6. Bornstein B, Area E, Flanigan KM, et al. Mitochondrial DNA depletion syndrome due to mutations in the RRM2B gene. *Neuromuscul Disord*. 2008; 18: 453-459.
7. Bourdon A, Minai L, Serre V, et al. Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. *Nat Genet*. 2007; 39: 776-780.
8. Paquis-Flucklinger V, Pellissier JF, Camboulives J, et al. Early-onset fatal encephalomyopathy associated with severe mtDNA depletion. *Eur J Pediatr*. 1995; 154: 557-562.
9. tojanovic V, Mayr JA, Sperl W, et al. Infantile peripheral neuropathy, deafness, and proximal tubulopathy associated with a novel mutation of the RRM2B gene: case study. *Croat Med J*. 2013; 54: 579-584.
10. Acham-Roschitz B, Plecko B, Lindbichler F, et al. A novel mutation of the RRM2B gene in an infant with early fatal encephalomyopathy, central hypomyelination, and tubulopathy. *Mol Genet Metab* 2009; 98: 300-304.
11. Pitceathly RD, Smith C, Fratter C, et al. Adults with RRM2B-related mitochondrial disease have distinct clinical and molecular characteristics. *Brain*. 2012; 135: 3392-3403.
12. Shaibani A, Shchelochkov OA, Zhang S, et al. Mitochondrial neurogastrointestinal encephalopathy due to mutations in RRM2B. *Arch Neurol*. 2009; 66: 1028-1032.
13. Spinazzola A, Invernizzi F, Carrara F, et al. Clinical and molecular features of mitochondrial DNA depletion syndromes. *J Inher Metab Dis*. 2009; 32: 143-158.
14. Horga A, Pitceathly RD, Blake JC, et al. Peripheral neuropathy predicts nuclear gene defect in patients with mitochondrial ophthalmoplegia. *Brain*. 2014; 137: 3200-3212.
15. Hernández-Lain A, Guerrero AM, Domínguez-González C, et al. A novel RRM2B gene variant associated with Telbivudine-induced mitochondrial myopathy. *J Neurol Sci*. 2015; 358: 481-483.

Correspondence to:

Finsterer J, MD, PhD
 Postfach 20
 1180 Vienna
 Austria, Europe
 E-mail: fifigs1@yahoo.de